Quarterly report [Sections 13 or 15(d)]

Earnings (Loss) per Share (Tables)

v3.25.3
Earnings (Loss) per Share (Tables)
 9 Months Ended
Sep. 30, 2025
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Earnings Per Share, Including Antidilutive Securities Excluded from Computation of Earnings Per Share
Basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2025 and 2024, respectively, consisted of the following (in thousands, except per share data):
Three Months Ended
September 30,		 Nine Months Ended
September 30,
2025 2024 2025 2024
Numerator (Basic and Diluted):
Net income (loss) $ 240  $ (5,385) $ (15,217) $ (20,910)
Change in value for stock settled consideration(1)
—  8  5  33 
Adjusted net income (loss) $ 240  $ (5,377) $ (15,212) $ (20,877)
Denominator:
Basic
Weighted average common shares issued and outstanding 39,030 38,778 38,999 38,645
Deduct: Unvested RSAs (2)
(17) (16) (17) (16)
Weighted average common shares outstanding 39,013 38,762 38,982 38,629
Basic earnings (loss) per common share $ 0.01  $ (0.14) $ (0.39) $ (0.54)
Diluted
Weighted average common shares outstanding from above 39,013 38,762 38,982 38,629
Add: Dilutive effect of RSUs, RSAs, PSUs & ESPP(3)
162 — — —
Add: Contingently issuable shares(1)(3)
— — — —
Weighted average common shares outstanding 39,175 38,762 38,982 38,629
Diluted earnings (loss) per common share $ 0.01  $ (0.14) $ (0.39) $ (0.54)
Antidilutive shares excluded from diluted earnings (loss) per common share(4)
755 1,001 1,096 1,116
(1)Relates to contingently issuable stock settled consideration.
(2)RSAs were issued to the non-employee directors and will vest in full on the earlier of the first anniversary of the date of grant or the next annual meeting of stockholders, subject to service requirements. See Note 9 – “Stock-Based Compensation Plans” for additional information.
(3)Shares related to the Company's RSUs, RSAs, PSUs, Amended ESPP, and contingently issuable shares were excluded from the weighted average common shares outstanding for the nine months ended September 30, 2025 and the three and nine months ended September 30, 2024 because inclusion of such shares would be antidilutive in a period of loss.
(4)Primarily pertaining to RSU grants to the Company’s employees and independent contractors.